share_log

百利天恒(688506.SH):注射用BL-B16D1项目治疗晚期实体瘤获得I期临床试验批准通知书

Baili Tianheng (688506.SH): BL-B16D1 for injectable treatment of advanced solid tumors obtained approval notice for phase I clinical trials

Gelonghui Finance ·  May 9 07:52

Gelonghui, May 9丨Baili Tianheng (688506.SH) announced that the self-developed innovative biopharmaceutical BL-B16D1 (dual antibody ADC) recently received the “Drug Clinical Trial Approval Notice” officially approved and issued by the National Drug Administration (NMPA). BL-B16D1 is a dual anti-ADC drug independently developed by the company and conjugated to a new generation of toxins. Its indications are advanced solid tumors.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment